Imunon, Inc. (IMNN) Key Statistics & Financial Ratios

Imunon, Inc. (IMNN) — Price $1.41 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Imunon, Inc. (IMNN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications.

Stock Data

Price$1.41
Market Cap$6M
Enterprise Value$6.9M
Beta2.12
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-0.31
Price / Book1.75
P/S0.00
EV/EBITDA-0.49
EV/Sales0.00
EV/FCF-0.00
P/FCF-0.00
Earnings Yield-199.45%
FCF Yield-68723.99%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity-314.89%
Return on Assets-98.17%
Return on Invested Capital-122.18%
Return on Capital Employed-145.30%

Financial Health

Current Ratio1.82
Quick Ratio1.82
Cash Ratio1.44
Debt / Equity1.87
Debt / Assets52.34%
Net Debt / EBITDA-0.07
Interest Coverage-191.99

Per-Share Data

Revenue per share0.00
Book Value per share0.80
Cash per share1.31
FCF per share-778.17
Tangible Book Value per share0.80
Dividend per share0.00

Related companies: AEON · BOLT · CING · CLRB · COCP · DWTX · EVGN

Explore sector: Healthcare · Biotechnology

More sections of IMNN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks